Ceruletide, a cholecystokinin analogue, has been reported to interact
with dopamine in the CNS and to benefit schizophrenic individuals. The
authors, using a double-blind design, a higher total dose, and a larger
sample size than previous studies, found no evidence of benefit.Abstract Teaser